Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Mar 21;12(4):933–947. doi: 10.1007/s13555-022-00696-z

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Fig. 1 — Algorithm for the treatment of infants, children, adolescents, and adults with mild-to-moderate AD. AD atopic dermatitis, EU European Union, TCI topical calcineurin inhibitors, TCS topical corticosteroids. *Pimecrolimus 1% cream is indicated for mild-to-moderate AD (children aged ≥ 2 years, adolescents, and adults) [53] and for use in infants aged ≥ 3 months (Australia, Brazil, Canada, European Union, India, Indonesia, Israel, New Zealand, Philippines, Russia, Taiwan, and Thailand only) [55–66]. **Pimecrolimus is recommended in EU guidelines [19] in sensitive skin areas; evidence suggests patient preference for pimecrolimus versus tacrolimus [100]. ***Pimecrolimus is recommended in other body locations versus tacrolimus, as there is a body of evidence to support its efficacy and tolerability profile. ^†TCI: pimecrolimus 1% cream, or tacrolimus 0.1% (aged ≥ 16 years) or 0.03% (aged 2–15 years) ointment; pimecrolimus is indicated for mild-to-moderate AD, and tacrolimus is indicated for moderate-to-severe AD [53, 54]